Striational antibodies in a paraneoplastic context

Muscle and Nerve

Volumn 47, Issue 4, 2013, Pages 585-587

  Mckeon, Andrew ^a   Lennon, Vanda A ^a   Lachance, Daniel H ^a   Klein, Christopher J ^a   Pittock, Sean J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antibody; Paraneoplastic; Sarcoma; Striational; Thymoma

Indexed keywords

ANTIBODY; STRIATIONAL ANTIBODY; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; AGED; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CANCER PATIENT; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HUMAN; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; PERNICIOUS ANEMIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SARCOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE PROTEINS; MYASTHENIA GRAVIS; NEOPLASMS; PARANEOPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; SARCOMA; THYMOMA; THYMUS NEOPLASMS;

EID: 84875617765     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23774     Document Type: Article

References (22)

1. Williams CL, Lennon VA, Momoi MY, Howard FM Jr. Serum antibodies and monoclonal antibodies secreted by thymic B-cell clones from patients with myasthenia gravis define striational antigens. Ann NY Acad Sci 1987;505:168-179.
2. Williams CL, Hay JE, Huiatt TW, Lennon VA. Paraneoplastic IgG striational autoantibodies produced by clonal thymic B cells and in serum of patients with myasthenia gravis and thymoma react with titin. Lab Invest 1992;66:331-336.
3. Mygland A, Aarli JA, Matre R, Gilhus NE. Ryanodine receptor antibodies related to severity of thymoma associated myasthenia gravis. J Neurol Neurosurg Psychiatry 1994;57:843-846.
4. Strauss AJ, Smith CW, Cage GW, van der Geld HW, McFarlin DE, Barlow M. Further studies on the specificity of presumed immune associations of myasthenia gravis and consideration of possible pathogenic implications. Ann NY Acad Sci 1966;135:557-579.
5. Strauss AJ, van der Geld HW, Kemp PG Jr, Exum ED, Goodman HC. Immunological concomitants of myasthenia gravis. Ann NY Acad Sci 1965;124:744-766.
6. Vernino S, Lennon VA. Autoantibody profiles and neurological correlations of thymoma. Clin Cancer Res 2004;10:7270-7275.
7. Lennon V, Lambert EH, Whittingham S, Fairbanks V. Autoimmunity in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1982;5(suppl):S21-25.
8. Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 2004;56: 715-719.
9. Graus F, Vincent A, Pozo-Rosich P, Sabater L, Saiz A, Lang B, et al. Anti-glial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes. J Neuroimmunol 2005;165:166-171.
10. Griesmann G, Kryzer, TJ, Lennon, VA. Autoantibody profiles of myasthenia gravis and Lambert-Eaton myasthenic syndrome. In: Rose N, Hamilton RG, Detrick B, editors. Manual of clinical laboratory immunology. Washington, DC: ASM Press; 2002. p 1005-1012.
11. Keegan BM, Pittock SJ, Lennon VA. Autoimmune myelopathy associated with collapsin response-mediator protein-5 immunoglobulin G. Ann Neurol 2008;63:531-534.
12. Chan KH, Lachance DH, Harper CM, Lennon VA. Frequency of seronegativity in adult-acquired generalized myasthenia gravis. Muscle Nerve 2007;36:651-658.
13. Cikes N, Momoi MY, Williams CL, Howard FM Jr, Hoagland HC, Whittingham S, et al. Striational autoantibodies: quantitative detection by enzyme immunoassay in myasthenia gravis, thymoma, and recipients of D-penicillamine or allogeneic bone marrow. Mayo Clin Proc 1988;63:474-481.
14. Zilko PJ, Dawkins RL, Cohen ML. Penicillamine treatment of rheumatoid arthritis: relationship of proteinuria and autoantibodies to immune status. Proc R Soc Med 1977;70(suppl 3):118-122.
15. Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: an analysis of 26, 758 cases. Int J Cancer 2006;119:2922-2930.
16. Lahat G, Lazar A, Lev D. Sarcoma epidemiology and etiology: potential environmental and genetic factors. Surg Clin N Am 2008;88:451-481.
17. Sato T, Tamaoki N. Myoid cells in the human thymus and thymoma revealed by three different immunohistochemical markers for striated muscle. Acta Pathol Jpn 1989;39:509-519.
18. Deyrup AT, Haydon RC, Huo D, Ishikawa A, Peabody TD, He TC, et al. Myoid differentiation and prognosis in adult pleomorphic sarcomas of the extremity: an analysis of 92 cases. Cancer 2003;98:805-813.
19. Drenckhahn D, von Gaudecker B, Muller-Hermelink HK, Unsicker K, Groschel-Stewart U. Myosin and actin containing cells in the human postnatal thymus. Ultrastructural and immunohistochemical findings in normal thymus and in myasthenia gravis. Virchows Arch B Cell Pathol Incl Mol Pathol 1979;32:33-45.
20. Le Panse R, Berrih-Aknin S. Thymic myoid cells protect thymocytes from apoptosis and modulate their differentiation: implication of the ERK and Akt signaling pathways. Cell Death Differ 2005;12:463-472.
21. Willcox N, Leite MI, Kadota Y, Jones M, Meager A, Subrahmanyam P, et al. Autoimmunizing mechanisms in thymoma and thymus. Ann NY Acad Sci 2008;1132:163-173.
22. Kirchner T, Hoppe F, Schalke B, Muller-Hermelink HK. Microenvironment of thymic myoid cells in myasthenia gravis. Virchows Arch B Cell Pathol Incl Mol Pathol 1988;54:295-302.